Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study
- 744 Downloads
The cytogenetic and molecular data is recognized as the most valuable prognostic factor in acute myeloid leukemia (AML). Our aim was to systemically analyze the cytogenetics of Korean AML patients and to compare the cytogenetic profiles of various races to identify possible geographic heterogeneity. We retrospectively reviewed medical records of 2806 AML patients diagnosed at 11 tertiary teaching hospitals in Korea between January 2007 and December 2011. The most common recurrent chromosomal abnormality was t(8;21) (8.8 %, 238/2717), but t(15;17) showed an almost same number (8.6 %,235/2717). Among de novo AML, the most frequent aberrations were t(15;17), observed in 229 (10.7 %). The most common French-American-British (FAB) classification type was M2 (32.2 %), and recurrent cytogenetic abnormalities correlated with the FAB subtypes. Among 283 secondary AML cases, myelodysplastic syndrome was the most common predisposing factor. About 67.1 % of the secondary AML cases were associated with chromosomal aberrations, and chromosome 7 abnormalities (n = 45, 15.9 %) were most common. The incidence of FLT3 internal tandem duplication mutation was relatively low at 15 %. Our study reports certain similarities and differences in comparison to previous reports. Such discrepancies call for extensive epidemiological studies to clarify the role of genetic as well as geographic heterogeneity in the pathogenesis of AML.
KeywordsAcute myeloid leukemia Cytogenetics Chromosomal abnormalities Population study
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014R1A1A1002797).
Compliance with ethical standards
This study was conducted according to the Declaration of Helsinki and was approved by the institutional review board of all the participating hospitals. In light of the retrospective nature of the study, informed consent was waived.
Conflict of interest
No conflict of interest to disclose.
- 3.Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336CrossRefPubMedGoogle Scholar
- 5.Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365CrossRefPubMedGoogle Scholar
- 11.Shaffer LG (2009) ISCN: an international system for human cytogenetic nomenclature. Karger, BaselGoogle Scholar
- 12.Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13):4075–4083PubMedGoogle Scholar
- 15.Park SH, Lee HJ, Kim IS, Kang JE, Lee EY, Kim HJ et al (2015) Incidences and prognostic impact of c-KIT, WT1, CEBPA, and CBL mutations, and mutations associated with epigenetic modification in core binding factor acute myeloid leukemia: a multicenter study in a Korean population. Annals Laboratory Med 35(3):288–297CrossRefGoogle Scholar
- 17.Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1312–1320CrossRefPubMedGoogle Scholar
- 20.So CC, Wan TS, Chow JL, Hui KC, Choi WW, Lam CC, Chan LC (2011) A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet 204(8):430–438CrossRefPubMedGoogle Scholar
- 25.Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96(4):1247–1253PubMedGoogle Scholar
- 26.Park SS, Cho HI (1997) The t(15;17) breakpoint of the PML gene in acute promyelocytic leukemia. Korean J Clin Pathol 17(6):885–897Google Scholar
- 34.Preiss BS, Bergmann OJ, Friis LS, Sorensen AG, Frederiksen M, Gadeberg OV et al (2010) Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. Cancer Genet Cytogenet 202(2):108–122CrossRefPubMedGoogle Scholar
- 35.Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z et al (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16(12):2366–2378CrossRefPubMedGoogle Scholar
- 36.Bang SM, Ahn JY, Park J, Park SH, Park J, Cho EK et al (2008) Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. J Korean Med Sci 23(5):833–837Google Scholar